Abstract
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder characterized by cutaneous hyperactivity to environmental triggers. Metallothionein (MT) is known for its defensive role against noxious stimuli, yet its specific function in AD development has remained unclear. This study utilizes a dinitrofluorobenzene (DNFB)-induced AD-like murine model to investigate the dynamic expression of MT. Our findings reveal that while AD-like lesions and thymic stromal lymphopoietin (TSLP) expression peak early (Day 1), MT expression in lesional skin peaks later (Day 3) and translocates to the cell nucleus. Comparative studies using MT-1/2 knockout ($MT^{-/-}$) mice demonstrated significantly more severe clinical symptoms and inflammatory markers compared to wild-type mice. These results suggest that MT serves as a protective endogenous shield against AD, likely through antioxidant and nuclear protective mechanisms.
Introduction
Atopic dermatitis (AD) is a relapsing inflammatory skin disease defined by a compromised skin barrier and Th2-mediated immune responses. Metallothioneins (MTs) are small, metal-binding proteins that protect cells from heavy metals, UV radiation, and oxidative stress. However, whether MT acts as a passive marker of damage or an active protective agent in AD was previously unknown. This research aimed to clarify the role of MT in dampening the inflammatory response in eczema-like conditions.
Methods
Researchers employed a DNFB-induced murine model to simulate human AD. DNFB application topically shifts the immune response toward a Th2-type profile. The study compared wild-type ($MT^{+/+}$) mice with MT-1/2 knockout ($MT^{-/-}$) mice. Dynamic expression profiling was conducted at Days 1, 3, 7, and 14 to track disease progression and MT response. Techniques included immunohistochemistry to observe cellular translocation, flow cytometry for immune cell infiltration (CD4+ T cells), and oxidative stress assays measuring Superoxide Dismutase (SOD) and Malondialdehyde (MDA).
Key Results and Insights
Dynamic Progression of Lesions and MT Expression
The study found a distinct temporal relationship between skin damage and the body's MT response. Clinical symptoms, including erythema and edema, reached their maximum severity at Day 1 following the establishment of the model.
In contrast, the expression of MT-2 mRNA in the lesional skin did not peak until Day 3. This lag suggests that MT production is a reactive, protective response triggered by the initial inflammatory insult.
MT as a Functional Shield
The protective role of MT was confirmed by the significantly worse clinical outcomes in $MT^{-/-}$ mice. These mice exhibited higher edema scores, increased skin thickness, and greater lesional skin weight compared to wild-type controls. Furthermore, $MT^{-/-}$ mice showed higher levels of TSLP—a master regulator of AD—and increased infiltration of CD4+ T cells.
Nuclear Translocation and Antioxidant Defense
A key finding was the translocation of MT from the cytoplasm to the cell nucleus during the peak of inflammation (Day 3). This suggests that MT may protect genomic DNA from oxidative damage. In the absence of MT, the body showed a compensatory but insufficient increase in other antioxidant markers like SOD and NDUFAF1, highlighting MT's unique and essential role in the skin's defense system.
Conclusion
This study demonstrates that Metallothionein is a crucial endogenous factor that mitigates the severity of atopic dermatitis-like inflammation. By acting as an antioxidant and potentially protecting nuclear integrity, MT limits tissue damage and modulates the immune response. Future research into topical MT-mimetic therapies or agents that induce endogenous MT expression could provide new treatment pathways for patients with chronic eczema.
Summary updated